4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

• 50 years of age

• Diagnosed with macular CNV secondary to AMD

• BCVA ETDRS Snellen equivalent for dose escalation and contralateral eye between 20/32 and ~20/320, or for dose expansion and population extension between ~20/25 and20/200, for steroid optimization and shedding sub-study between ~20/25 and ~20/640

• Currently receiving anti-VEGF treatment in the study eye and has demonstrated aclinical response consistent with anti-VEGF activity within 12 months prior toscreening

Contralateral Eye Sub-study-Specific Criteria: Received 4D-150 in study eye-1 at least 6 months prior to Contralateral Sub-study Screening Visit

Contralateral Eye Sub-study-specific Exclusion: Prior adverse event related to 4D-150, required modifications to or reinitiated protocol specified corticosteroid regimen/taper in study eye-1, signs and symptoms of noninfectious intraocular inflammation in either eye

• Shedding Sub-study-specific Inclusion Criteria:

S-1. ≥50 years of age S-2. Diagnosed with macular CNV secondary to AMD S-3. BCVA ETDRS Snellen equivalent between ~20/640 and 20/25 S-5. Currently receiving anti-VEGF and has demonstrated a clinical response consistent with anti-VEGF activity within 12 months prior to screening

Shedding Sub-study-specific Exclusion Criteria:

• Any condition preventing visual acuity improvement in the study eye

• Prior treatment with photodynamic therapy or retinal laser in the study eye

• History of uveitis in either eye

• Any other pre-existing eye conditions or surgical complications that would precludeparticipation in an interventional clinical trial or interfere with theinterpretation of study endpoints